Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1–10 results in antitumor activity in human neuroblastoma

In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model

(2015) Libo Zhang et al.   NEOPLASIA

Mechanisms of resistance to antiangiogenesis therapy

(2010) Faisal Azam et al.   EUROPEAN JOURNAL OF CANCER

The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts

(2010) Jochen Rössler et al.   INTERNATIONAL JOURNAL OF CANCER

Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2-Neutralizing Peptibody

(2010) A. Coxon et al.   MOLECULAR CANCER THERAPEUTICS

Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth

(2009) Patrick Nasarre et al.   CANCER RESEARCH

Anticancer strategies involving the vasculature

(2009) Victoria L. Heath et al.   Nature Reviews Clinical Oncology

Angiopoietin-2: Development of inhibitors for cancer therapy

(2009) Bo Hu et al.   Current Oncology Reports

Angiopoietin-2 Stimulates Blood Flow Recovery After Femoral Artery Occlusion by Inducing Inflammation and Arteriogenesis

(2008) Sarah L. Tressel et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Reduced Glioma Growth Following Dexamethasone or Anti-Angiopoietin 2 Treatment

(2008) Jérôme Villeneuve et al.   BRAIN PATHOLOGY

Angiogenesis as a target in neuroblastoma

(2008) Jochen Rössler et al.   EUROPEAN JOURNAL OF CANCER

Inhibition of In Vivo Tumor Angiogenesis and Growth Via Systemic Delivery of an Angiopoietin 2-Specific RNA Aptamer

(2008) Shiva Sarraf-Yazdi et al.   JOURNAL OF SURGICAL RESEARCH